Pharmaceutical company Double Bond Pharma continues to report no revenues and minor changes in results in the second quarter, while the company is working on an in-depth analysis of the RWE study and a rollout of Temodex in selected markets.Operating profit amounted to -0.6 million kronor (-0.4). Profit after tax amounted to -0.6 million kronor (-0.4). Earnings per share amounted to -0.00 kronor (-0.01).CEO Igor Lokot states that the company is engaged in intensive negotiations with potential partners and has made further progress in discussions with four counterparties, two of which are pharmaceutical companies and two of which are financial investors.However, the negotiations have taken longer because the company is preparing a supplementary cohort analysis of patient groups based on MGMT status to strengthen the evidentiary value of the RWE study. The analysis is expected to start in the autumn and continue for a few months.In parallel, the company is working to commercialize Temodex in three markets. In Turkey, a letter of intent has been signed; in China, the design of a so-called bridging study is being prepared; and in Mexico, the registration dossier is being finalized.No financial forecast is provided.Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeTotal revenues0,00,0-Operating profit-0,6-0,4Net profit-0,6-0,4Earnings per share, kronor-0,00-0,01